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Background: Estimates of the interval from HIV-1 infection to disease progression may be affected by selection
bias, and data concerning asymptomatic early seroconverters are limited. We examined the interval until disease
progression in HIV-1 seroconverters in whom the timing of infection could be estimated within 1 year before
diagnosis.
Methods: Subjects included newly diagnosed patients at Osaka National Hospital between 2003 and 2010 who
had either (1) symptomatic acute HIV-1 infection with a negative or intermediate reaction on Western blotting
and a positive reaction on an HIV RNA test (symptomatic acute group) or (2) a positive reaction on Western
blotting at diagnosis and a <1-year interval from the last negative HIV test until the first positive test. The latter
was divided into symptomatic recent or asymptomatic recent groups based on the presence or absence,
respectively, of any transient fever between the last negative and first positive tests. Disease progression was
defined as a fall in the CD4 count to <350 cells/microL on 2 consecutive tests, the start of anti-HIV therapy, or the
onset of AIDS-indicator diseases. Information was retrospectively collected from medical records.
Results: Subjects included 210 patients: 91 in the symptomatic acute group, 72 in the symptomatic recent group,
and 47 in the asymptomatic recent group. In the symptomatic acute (0.8 years) and symptomatic recent
(2.2 years) groups, the Kaplan-Meier estimate of median interval until disease progression was significantly shorter
than that in the asymptomatic recent group (2.9 years). Multivariate analysis by Cox’s proportional hazards test
showed that the symptomatic acute group (vs. asymptomatic recent group: hazard ratio: 1.93; 95% confidence
interval: 1.14–3.36; p = 0.0140) and a baseline CD4 count of <400 cells/microL (hazard ratio: 3.88; 95% confidence
interval: 2.57–5.96; p < 0.0001) were independent prognostic factors associated with early disease progression.
Conclusions: Symptomatic seroconversion was associated with early disease progression. Furthermore, the
estimated median interval until the CD4 count was <350 cells/microL was only 2.9 years even in patients with
asymptomatic seroconversion. These results suggest the importance of early diagnosis in early seroconverters.
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Studies in the late 1980s reported that the asymptomatic
phase persisted for about 10 years in patients infected
with human immunodeficiency virus (HIV)-1 [1-4].
However, various observational studies and meta-
analyses have indicated that the baseline CD4-positive
T-lymphocyte count (CD4 cell count) of the patients in-
fected with HIV-1 in recent years is lower than that in
previous studies, and that the plasma HIV-1-RNA level
at the set point is higher [5-10], suggesting the possibil-
ity that HIV-1 has become more virulent and the asymp-
tomatic phase has been shorter [11,12].
After primary infection with HIV-1, symptoms such as
fever, lymph node swelling, and headache appear in
40%–90% of patients [13]. Fever is the most common
symptom related to primary HIV-1 infection [14-16]. A
cohort study involving patients with symptomatic acute
HIV-1 infection is one way to observe and evaluate the
spontaneous course of HIV-1 infection. However, there
are some limitations regarding observational studies in-
volving patients with symptomatic acute HIV-1 infec-
tion. In these patients, the disease progression is more
rapid than in those with asymptomatic acute HIV-1 in-
fection [17-20]. In addition, the severity of acute HIV-1
infection is also associated with disease progression
[15,16,18]. Therefore, the spontaneous history in pa-
tients with symptomatic acute HIV-1 infection does not
always reflect that of HIV-1 infection overall. In a cohort
study involving early HIV-1 seroconverters, the propor-
tion of patients with symptoms was also high, suggesting
the presence of a selection bias [12,18].
With the appearance of new anti-HIV drugs and an
accumulation of evidence, it has been recommended
that antiretroviral therapy (ART) should be introduced
in patients with a high CD4-positive T lymphocyte count
(CD4 cell count). In Japanese guidelines, the CD4 cell
count cutoff for the start of ART also increased from
200 to 350 cells/μL in 2008 and then to 500 cells/μL in
2013. However, the estimated interval from HIV infec-
tion until the CD4 cell count decreases to 350 cells/μL is
still important for evaluating the timing of ART initi-
ation. Concerning recent reports [5,16,20-27] of the esti-
mated interval until disease progression, limitations of
selection bias may be present as described above. In
addition, data concerning asymptomatic early serocon-
verters are limited. We therefore focused on the charac-
teristics of HIV-1 seroconverters both with and without
symptoms related to primary HIV-1 infection. In this
study, patients newly diagnosed based on positive reac-
tions on Western blotting were investigated. Those in
whom the timing of HIV-1 infection could be estimated
to have been within 1 year before the HIV-1 infection
diagnosis were divided into 2 groups with respect to the
presence or absence of a history of fever between the lastnegative and first positive tests. We examined the char-
acteristics by comparing the clinical course between




Of 1199 patients newly diagnosed with HIV-1 infection
between 2003 and 2010 at the National Hospital
Organization Osaka National Hospital, in 210, the tim-
ing of HIV-1 infection could be estimated within 1 year
before their diagnosis. Ninety-five symptomatic patients
had a negative or intermediate reaction detected on
Western blotting at the time of HIV-1 infection diagno-
sis, and the polymerase chain reaction (PCR) method
showed a positive reaction. Of these, 4 were diagnosed
with chronic infection based on the changes in the
Western blotting results, clinical course, and absence of
a recent risk of infection. Therefore, 91 were diagnosed
with symptomatic acute HIV infection (symptomatic
acute group). In 119 patients, a positive reaction was de-
tected on Western blotting at the time of HIV-1 infec-
tion diagnosis and the interval from the last negative
test until the first positive test was ≤1 year (recent
group). Of these, 72 reported having a transient fever be-
tween the last negative and first positive tests (symptom-
atic recent group). The other 47 patients were assigned
to the asymptomatic recent group.
Patient characteristics and comparisons among
symptomatic acute, symptomatic recent, and
asymptomatic recent groups
Patient characteristics are shown in Table 1. The demo-
graphic and clinical characteristics of the subjects were
compared among the symptomatic acute, symptomatic
recent, and asymptomatic recent groups. There were no
differences in the age or estimated route of infection
among these 3 groups. In the symptomatic acute and
symptomatic recent groups, the proportion of patients
diagnosed in the late phase (2007–2010) was higher than
that of patients diagnosed in the early phase (2003–
2006). In the symptomatic recent group, 46 patients
(64%) consulted a hospital for fever between the last
negative and first positive tests. However, no HIV test
was performed in any patient. The interval from the last
negative test until the first positive test was compared
between the symptomatic recent and asymptomatic re-
cent groups. In the former (median 7.1 months), it was
significantly shorter than in the latter (median
10.1 months), suggesting that a diagnosis of HIV infec-
tion was made earlier in the symptomatic recent group.
Information regarding HIV-1 subtype was available in
111 of 210 participants. The most common subtype was
B (n = 108), followed by CRF_01AE (n = 3). The









Number of participants 91 72 47
Age at first visit (y), median [IQR] 33 [28–38] 30 [25–35] 31 [24–36] 0.0841
Men, n (%) 91 (100%) 69 (97%) 47 (100%) 0.0387
Estimated route of transmission, n (%)
Homosexual 79 (87%) 66 (92%) 43 (92%) 0.3234
Heterosexual 9 (10%) 6 (8%) 2 (4%)
Unknown 3 (3%) 0 (0%) 2 (4%)
HIV-1 subtype
B 41 (45%) 40 (56%) 27 (57%) 0.0983
CRF01_AE 0 (0%) 1 (1%) 2 (4%)
Not determined 50 (55%) 31 (43%) 18 (38%)
Nationality, n (%)
Japanese 89 (98%) 70 (97%) 47 (100%) 0.3490
Other 2 (2%) 2 (2%) 0 (0%)
Calendar year at diagnosis, (%)
2007–2010 65 (71%) 45 (63%) 20 (43%) 0.0044
2003–2006 26 (29%) 27 (37%) 27 (57%)
Medical exam between last negative and first positive test,
n (%)
No 3 (3%) 26 (36%) 47 (100%) <0.0001
Outpatient 28 (31%) 36 (50%) 0 (0%)
Hospitalization 60 (66%) 10 (14%) 0 (0%)
Interval between last negative and first positive test (mo),
median [IQR]
7.1 [4.1–10.2] 10.1 [6.1–11.7] 0.0472
Baseline CD4 cell count (cells/μL), median [IQR] 359 [243–464] 353 [257–481] 445 [353–526] 0.0323
Percentage of patients with CD4 cell count <400 cells/μL, n
(%)
54 (59%) 43 (60%) 15 (31%) 0.0035
Baseline HIV-1 RNA level (copies/mL), median [IQR] 470000 [52000–270000] 32000 [6900–74800] 21000 [12000–66000] <0.0001
Percentage of patients with HIV-1 RNA level ≥50000 copies/
mL, n (%)
69 (76%) 26 (36%) 14 (30%) <0.0001
Abbreviation: IQR, interquartile range
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was not statistically different among the symptomatic
acute, symptomatic recent, and asymptomatic recent
groups (Table 1) and was not changed from the early
phase (2003–2006, 55%) to the late phase (2007–2010,
49%) (p = 0.1900).
Comparison of baseline CD4 cell count and plasma HIV-1
RNA level
We examined the CD4 cell count and viral level on the
initial consultation. Overall, the median CD4 cell count
and plasma HIV-1 RNA level were 383 cells/μL and
51,900 copies/mL, respectively. The proportion of pa-
tients with a CD4 cell count of <400 cells/μL and that of
patients with a plasma HIV-1-RNA level of ≥50,000 cop-
ies/mL are presented in Table 1. In the symptomaticacute and symptomatic recent groups, the proportions
of patients with a baseline CD4 cell count of <400 cells/
μL were higher than that in the asymptomatic recent
group (symptomatic acute vs. asymptomatic recent: p <
0.01; symptomatic recent vs. asymptomatic recent: p <
0.01). Furthermore, the proportion of patients with a
baseline plasma HIV-1-RNA level of ≥50,000 copies/mL
was the highest in the symptomatic acute group among
the 3 groups (symptomatic acute vs. asymptomatic re-
cent: p < 0.001; symptomatic acute vs. symptomatic re-
cent: p < 0.001).
Estimated interval from HIV-1 infection until disease
progression
We examined the interval from the estimated timing of
infection until disease progression. Twelve patients
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gardless of their CD4 cell counts, were excluded from the
analysis. Of the 198 patients, 119 met the criteria for dis-
ease progression during the follow-up period (median
0.78 years). Of these, 96 patients showed a CD4 cell count
of <350 cells/μL on 2 consecutive tests. In the other 19
patients who had a CD4 cell count of <350 cells/μL on at
least 1 test, ART was started (9 in the acute symptomatic
phase and 6 in the chronic asymptomatic phase) or AIDS-
indicator diseases were diagnosed before the above
criterion was met. In the remaining 4, although the CD4
cell count did not reach <350 cells/μL on either test, ART
was started for prevention of partner infection, HBV
infection, thrombocytopenia, and HIV infection-related
malaise in each patient. In the symptomatic acute group,
in only one of the patients with a CD4 cell count of <350
cells/μL on the first and second tests did the CD4 cell
count return to ≥350 cells/μL within the next 3 months.
Using the Kaplan-Meier method, we estimated the
interval from the estimated timing of infection until
disease progression. In the cohort overall, the median
interval until disease progression was 1.9 years. In the
symptomatic acute, symptomatic recent, and asymptomatic
recent groups, it was 0.8, 2.2, and 2.9 years, respectively
(Figure 1), showing significant differences (symptomatic
acute vs. symptomatic recent: p < 0.001; symptomatic acute
vs. asymptomatic recent: p < 0.001; symptomatic recent vs.
asymptomatic recent: p < 0.05). Using Cox’s proportional
hazards model, we investigated factors involved in early
disease progression (Table 2). On univariate analysis, a
baseline CD4 cell count of <400 cells/μL, and belonging to
the symptomatic acute group were significant factors.
Multivariate analysis showed that the baseline CD4 cell

































Log rank p <0.0001
Estimated interval
from HIV-1 infection (years)
81 29 11 4 3 1Symptomatic acute
No. at risk
71 39 25 12 5 3Symptomatic recent
Asymptomatic recent 46 32 23 16 11 8 6 2 1
Figure 1 Kaplan-Meier plot of the cumulative rate of disease
progression in the study participants. Comparison of the cumulative
rate of disease progression among the symptomatic acute,
symptomatic recent, and asymptomatic recent groups.independent factors. To verify the results of multivariate
analysis, we conducted subgroup analysis by stratification
of the CD4 cell count on the initial consultation (Figure 2).
In the symptomatic acute group, disease progression was
observed in the early stage regardless of the baseline CD4
cell count. However, the interval until disease progression
was similar between the symptomatic recent and
asymptomatic recent groups through stratification. These
results showed that the interval from HIV infection until
disease progression was associated with the CD4 cell count
on the initial consultation, a diagnosis of acute HIV
infection, and fever suggestive of primary infection with
HIV-1 and that the former 2 were independent factors.
Discussion
This study was conducted in HIV-1 seroconverters in
Osaka (Japan) in whom the timing of infection could be
estimated within 1 year before diagnosis. Initially, as im-
portant observation points, disease progression was
noted in the early stage in symptomatic HIV-1 serocon-
verters. In those diagnosed in the acute stage of HIV-1,
the median interval until disease progression was only
0.8 years (Figure 1). Although some studies have esti-
mated the interval from infection until the CD4 cell
count reaches <350 cells/μL in patients with acute HIV-
1 infection [5,16,20-24,26,27], it is difficult to compare
the results among different cohorts due to differences in
the definition of acute HIV-1 infection and disease pro-
gression or patient background. However, similar median
intervals have been reported from Japan (<1 year) [16],
Holland (<1 year) [24], and Germany (8.3 months) [26],
although some reports showed longer median intervals
than this report does [5,20,21,23,27]. The reasons sug-
gested for early disease progression include host-related
factors such as genetic background, route of infection,
and social background; viral factors such as subtype and
escape mutations; and the possibility of a selection bias
in which severe-status patients were predominantly en-
rolled in the study [28,29]. The mechanism of early dis-
ease progression remains to be clarified, but it must be
considered that disease progression is rapid in patients
with symptomatic acute HIV-1 infection.
Even in patients without primary infection symptoms
(asymptomatic recent group), the median interval from
infection until disease progression was 2.9 years. In a
large-scale observational study involving 18,495 serocon-
verters, the interval from infection until the CD4 cell
count reached <350 cells/μL was estimated to be
4.19 years [25]. However, approximately 50% of the
study subjects had been diagnosed with HIV-1 infection
before 1996. The subjects included patients with symp-
tomatic acute HIV infection. Therefore, although the
interval from infection until the CD4 cell count reached
<350 cells/μL is longer than what we report here, a
Table 2 Association with early disease progression in early HIV-1 seroconverters
Univariate results Multivariate results
HR 95% CI p value HR 95% CI p value
Age (≥40 vs. <40) 1.21 0.73–1.93 0.4411 1.25 0.75–2.00 0.3739
Calendar year at diagnosis (2007–2010 vs. 2003–2006) 1.36 0.93–2.03 0.1170 1.26 0.83–1.93 0.2823
With baseline CD4 cell count <400 cells/μL 4.02 2.70–6.08 <0.0001 3.88 2.57–5.96 <0.0001
Group
Asymptomatic recent group 1 1
Symptomatic recent group 1.62 0.97–2.74 0.0621 1.12 0.67–1.93 0.6772
Symptomatic acute group 2.95 1.79–4.99 <0.0001 1.93 1.14–3.36 0.0140
Abbreviations: HR, hazard ratio; CI, confidence interval.
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ours is not possible.
Of the 119 patients with positive reactions on Western
blotting at the time of HIV-1 infection diagnosis, symp-
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from HIV-1 infection(years)
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Figure 2 Kaplan-Meier plot of the cumulative rate of disease
progression stratified with the CD4 cell count. (A) Patients with a
CD4 cell count of <400 cells/μL on the initial consultation. (B)
Patients with a baseline CD4 cell count of 400 cells/μL or more.were observed in 72. However, this figure may include
an error. Although patients were questioned about a his-
tory of fever at the initial consultation, fever is not al-
ways related to primary HIV-1 infection. Furthermore,
we cannot rule out the possibility that some patients
could not recollect the appearance of symptoms related
to primary infection and were assigned to the asymp-
tomatic recent group. However, when analyzing the
HIV-1 RNA level (Table 1) and interval from infection
until disease progression (Figure 1), the symptomatic
acute and asymptomatic recent groups showed opposite
characteristics. Those of the symptomatic recent group
were intermediate between the other 2 groups. Based on
these results, we believe the majority of participants
were assigned to the correct groups. Several possibilities
may explain why the symptomatic acute and symptom-
atic recent groups showed different disease progression.
One possible reason is the difference in disease severity
because the proportion of patients who were hospital-
ized in the symptomatic acute group was higher than
that in the symptomatic recent group (Table 1). How-
ever, we cannot exclude the possibility that recall bias, as
mentioned above, may have affected this difference.
As shown in Table 1, the interval from the last nega-
tive test until the first positive test in the symptomatic
recent group was significantly shorter than in the symp-
tomatic recent group. This suggests the possibilities that
the development of fever motivated those who recognize
the risk of HIV-1 infection to undergo voluntary HIV
testing and that the true seroconversion date with symp-
tomatic seroconverters would be closer to the date of
the first positive test rather than the date of the last
negative test. These possibilities were also indicated by
the recent report estimating the date of infection for
HIV-1 infected patients using the HIV-1-specific im-
munoglobulin G (IgG) levels measured by the IgG-
capture BED-enzyme immunoassay [30].
A limitation of this study is that it was a retrospective
analysis involving a limited number of patients in a sin-
gle institution. We are also aware of possible limitations
of selection and recall biases in this study. Selection of
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fection could be a potential source of selection bias.
However, the data presented in this study are consistent
with the results of previous studies. Patients diagnosed
with acute HIV-1 infection showed disease progression
in the early stage. Fever related to primary HIV-1 infection
encouraged patients undergo HIV testing. Additionally,
disease progression may be observed within a relatively
short period even in asymptomatic early-infection patients.
Conclusions
Symptomatic HIV-1 seroconversion was associated with
early disease progression, especially in patients with
symptomatic acute HIV-1 infection, with a median inter-
val until disease progression of only 0.8 years. Further-
more, the estimated median period during which the
CD4 cell count was <350 cells/μL was only 2.9 years
even in patients with asymptomatic seroconversion.
These results suggest the importance of early diagnosis
in early HIV-1 seroconverters.
Methods
Case selection
This study was conducted at the National Hospital
Organization Osaka National Hospital, a major hospital
for HIV infection in Japan, located in the center of
Osaka. Subjects included newly diagnosed patients with
HIV-1 infection who consulted this hospital for the first
time between 2003 and 2010 and who met 1 of the fol-
lowing 2 criteria: (1) a negative or intermediate reaction
detected on Western blotting at the time of HIV-1 infec-
tion diagnosis and a positive PCR, leading to a diagnosis
of symptomatic acute HIV-1 infection (symptomatic
acute group) or (2) a positive reaction detected on West-
ern blotting at the time of HIV-1 infection diagnosis and
a <1-year interval from the final negative HIV test until
the first positive HIV test (recent groups). The protocol
of this study was approved by the Ethics Review Board
of the National Hospital Organization Osaka National
Hospital (Approval No. 0913).
Measurement of the CD4 cell count, plasma HIV-1 RNA
level, and Western blotting
The CD4 cell count was measured by flow cytometry
using the single-platform method. Peripheral blood
(100 μL) was incubated with 10 μL of CYTO-STAT tet-
raCHROME reagent (Beckmann Coulter, Miami, FL)
containing CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5
monoclonal antibodies. After erythrocyte hemolysis and
cell fixation with the whole blood lysing reagent Kit
(Beckmann Coulter), 100 μL of Flow-Count fluoro-
spheres were added to the sample, and the absolute
CD45 + CD3 + CD4 + CD8– cell counts were measured
using a Cytomics FC500 system (Beckmann Coulter).The plasma HIV-1 RNA level was determined using the
reverse-transcription PCR method (COBAS AMPLICOR
HIV-1 test or COBAS TaqMan HIV-1 test; Roche Mo-
lecular Diagnostics, Branchburg, NJ). The CD4 cell
count and plasma HIV-1 RNA level were measured at 1-
to 4-month intervals. For Western blotting for HIV-1,
LAV Blot I (Bio-Rad Laboratories, Hercules, CA) was
used. Interpretation of the results was performed ac-
cording to the criteria established by the World Health
Organization.
Definition of the symptomatic acute, symptomatic recent,
and asymptomatic recent groups and comparison of
clinical information on the initial consultation among the
groups
The symptomatic acute group was defined as described
above. Patients meeting conditions for both the symp-
tomatic acute and recent groups were assigned to the
symptomatic acute group. In the recent group, any self-
reported history of a transient fever was investigated at
the initial consultation in our hospital. Fever was defined
as a body temperature of 38°C or higher. When a defini-
tive diagnosis of a disease that causes fever was made,
the patient was excluded from a history of fever. Patients
who recollected having a transient fever between the last
negative and first positive tests for HIV infection were
assigned to the symptomatic recent group, and those
who did not were assigned to the asymptomatic recent
group. Information on the age, sex, nationality, esti-
mated route of infection, year of diagnosis, previous hos-
pital consultations, CD4 cell count, and plasma HIV-1
RNA level was collected from medical records and com-
pared among the 3 groups.
Estimation of the timing of HIV-1 infection and interval
from infection until disease progression
In the symptomatic acute group, the timing of infection
was estimated to be 1 month before a diagnosis of HIV-
1 infection was made. In the recent groups, the midpoint
between the last negative and first positive tests was
regarded as the estimated timing of infection. The tim-
ing of disease progression was defined as the earliest
date on which the CD4 cell count was less than 350
cells/μL on 2 consecutive tests conducted at more than
1 month apart, the start of ART, or the onset of an
AIDS-indicator disease. In patients in whom the annual
frequency of testing for the CD4 cell count and plasma
HIV-1 RNA level became <3, follow-up was completed
on the final day of testing. The interval from the esti-
mated timing of infection until disease progression was
calculated using the Kaplan-Meier method. For signifi-
cance tests, the log-rank test was performed. When
there was a significant difference, adjustment was con-
ducted using Holm’s correction, and multiple tests were
Watanabe et al. AIDS Research and Therapy  (2015) 12:19 Page 7 of 8performed. For multivariate analysis, Cox’s proportional
hazards analysis was carried out. With respect to indi-
vidual factors, the hazard ratio, 95% confidence interval,
and p-value were calculated.Statistical analysis
For 3 × 2 cross-table tests, the χ2 test was used. When
there was a significant difference, adjustment was con-
ducted using Holm’s method, and multiple tests were
performed. To compare the results among the 3 groups,
analysis was conducted using Kruskal-Wallis one-way
analysis of variance by ranks. The Kaplan-Meier method,
log-rank test, and Cox’s proportional hazards test were
performed, as described above. For statistical analysis,
JMP version 10.0.0 software (SAS Institute, Cary, NC)
was used. A p-value of <0.05 was regarded as significant.
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